24/7 Market News Snapshot 01 July, 2025 – Lixte Biotechnology Holdings, Inc. Common Stock (NASDAQ:LIXT)

July 1, 2025

DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NASDAQ:LIXT) are discussed in this article.
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical firm specializing in advanced cancer therapies, is currently experiencing significant positive momentum in the market, reflecting growing investor interest. The stock opened at $1.03 and has gained an impressive 13.81%, with trading volumes reaching 12.49 million shares. This activity suggests increasing confidence among investors, which could lead to further upward price movement as market dynamics evolve.

In a strategic move to bolster its financial foundation, Lixte has announced a substantial financing initiative, entering into a definitive agreement with accredited investors aimed at raising approximately $5.0 million. This capital is being raised through a combination of Common Stock and Series B Convertible Preferred Stock, along with accompanying warrants. The offer includes 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants, aligning with Nasdaq regulations. Notably, Pre-Funded Warrants can be exercised immediately at a minimal price, offering investors a viable entry option, while the Common Warrants carry an exercise price of $1.00 per share.

The closing of this financing is expected to occur on July 2, 2025, pending customary conditions. The proceeds from this offering will be dedicated to general corporate purposes and essential working capital, facilitating the continued advancement of Lixte’s pioneering drug development efforts. Currently, the firm is focusing on its lead candidate, LB-100, a novel PP2A inhibitor undergoing trials for multiple types of cancers, including colon, small cell lung, and sarcoma. The company remains dedicated to transforming cancer treatment through innovative therapies, supported by a strong patent portfolio and a talented team of professionals. Stakeholders are encouraged to stay updated on Lixte’s progress in revolutionizing cancer care.

Related news for (LIXT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.